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Neonatal sclerosing cholangitis (NSC) is a rare form of severe liver disease first reported in 8 children presenting in early infancy with jaundice, hepatosplenomegaly, pale stools, and high serum γ-glutamyltransferase activity (GGT) [1] . Ductular proliferation, moderate portal-tract inflammation, and fibrosis were found at liver biopsy. Percutaneous cholangiography confirmed intrahepatic cholangiopathy in all; 2 had earlier undergone laparotomy to exclude biliary atresia (BA). Most developed biliary cirrhosis. Three patients were born to consanguine parents, suggesting recessive inheritance. The term NSC was first used for high-GGT neonatal-onset cholangiopathy in another consanguine sibling pair. Biliary cirrhosis required liver transplantation (LT) for survival [2] . A distinct hepatorenal disorder was later suggested in 2 siblings with renal disease, high GGT activity, and, on endoscopic retrograde cholangiopancreatography (ERCP) and liver biopsy, early-onset changes like those of primary sclerosing cholangitis [3] . Cholangiopathy in children has been attributed to immune dysregulation (autoimmune sclerosing cholangitis, immunodeficiency or Langerhans cell histiocytosis [4] ) and to single-gene disorders (deficiency of multidrug associated protein 3 (MDR3), encoded by ABCB4 [5] , claudin-1 deficiency [6] or Kabuki syndrome [7, 8] ); as with BA, it also may have multiple different causes [9] .
The aim of this study was to identify genes mutated in NSC patients seen at King's College Hospital [10] . We describe the clinical and laboratory features, presentation, and disease progression of NSC in these patients; the process and results of whole exome sequencing (WES) in a subgroup of these patients, with Sanger-sequencing confirmation of candidategene mutations and selective sequencing of candidate genes, when possible, in the remaining patients; and the findings within liver and biliary tract on immunohistochemical assessment of encoded-protein and comparison-protein expression as well as on ultrastructural study. Table S1 ). The remaining 11 patients subsequently underwent Sanger sequencing of DCDC2. Parental or patient consent had previously been obtained for research investigation in accordance with institutional guidelines. Ethical-review committee approval for this specific study was obtained, with samples anonymised before use.
Patients and Methods
Patients
Whole Exome Sequencing
WES was undertaken using the Roche Nimblegen SeqCap EZ Human Exome Library v2.0, as per manufacturer's protocol. Initial analysis focused on finding variants distributed in a pattern consistent with autosomal-recessive disease inheritance. WES to permit cataloguing of genetic variation in patients followed published protocols [11] . Variants were annotated with Variant Effect Predictor and loaded into Gemini software [12] . Variants with minorallele frequency > 1% in the 1000 Genome or the Exome Sequencing Project data were excluded, as were intergenic variants and variants that were flagged as low quality or potential false-positives (quality scores ≤ 30; long homopolymer runs > 5; low quality by depth < 5; occurrence within a cluster of single-nucleotide polymorphisms). Variants of interest (see above) were prioritised for biological relevance.
Sanger sequencing
Sanger sequencing confirmed variants identified by WES in the first set of patients. Forward and reverse primers were designed and annealing temperatures were set for genes of interest (Supplementary information, Table S2 ). PCR amplification and sequencing reactions were performed using standard protocols [13, 14] .
Histopathologic and ultrastructural studies
Archival formalin-fixed, paraffin-embedded liver-biopsy or hepatectomy materials obtained for clinical diagnosis were available from 12 of the 13 patients in whom WES was conducted.
For each patient, tissue sections were cut at 4 µ m and stained with haematoxylin-eosin and with orcein. To exclude MDR3 deficiency, parallel sections were immunostained with P311-26, a monoclonal antibody against MDR3 (Alexis Biochemicals ALX-801-028, Nottingham, UK); as a control, parallel sections also were immunostained with M2-lll-6, a monoclonal antibody against a homologous bile-canaliculus transporter, human multidrug resistanceassociated protein 2 (Alexis Biochemicals ALX-801-016-C250 Liver material from 5 probands, primarily fixed in paraformaldehyde / glutaraldehyde, either at bedside on sampling or on retrieval from -80°C storage, was post-fixed (OsO 4 ) and embedded in resin. Ultrathin sections stained with uranyl acetate / lead citrate were evaluated by transmission electron microscopy (TEM), with particular attention to cholangiocytes. NSC cases with no DCDC2 mutations, and other cholestatic disorders as described above, were used as controls for ultrastructural studies.
Results
Demographics
Twenty-nine children (15 male) from 24 families met inclusion criteria ( Table   S1 ).
Presenting features were jaundice (27) , pale stools (10) 
Histopathologic and ultrastructural studies
On biopsy at presentation in patients aged eight months or less, varying degrees of portal-tract fibrosis without oedema were found. Numbers of bile-duct profiles were increased in interlobular portal tracts, with occasional intraductal bile plugs ( Figure 1A ). Persistence of the ductal plate was identified in two patients (Patients 3 and 7). Two patients were biopsied In control material, DCDC2 was generally expressed by cuboidal cholangiocytes (neocholangioles, interlobular bile ducts, small septal bile ducts), but only faint focal marking was seen in columnar cholangiocytes (large septal bile ducts, hilar bile ducts, extrahepatic biliary tract with gallbladder). Similar findings were observed in liver material from the NSC patients with no DCDC2 mutations ( Figure 1E ). However, in patients with proven DCDC2 mutation, no expression of DCDC2 was found at any site ( Figure 1D ), consistent with absence of the protein.
Immunostaining for the primary-cilium protein ACALT, conducted to assess presence or absence of primary cilia at cholangiocytes, found good expression in small interlobular ducts as well as in larger septal and perihilar bile ducts ( Figure 3C, inset) . In DCDC2-mutated probands, however, ACALT expression was entirely absent in septal and perihilar bile ducts, with only very focal and irregular expression in interlobular bile ducts ( Figures 3C, 3D ). The findings suggested absence of normally constituted primary cilia in association with DCDC2 mutation.
In control tissue examined by TEM, primary ciliary structures were identified within interlobular bile ducts and neocholangioles ( Figure 3B ; green arrow). In the 5 probands with tissue available for TEM, lobular cytoplasmic necrosis, dilatation of canalicular lumina with amorphous bile, blunting of microvilli, and cytoplasmic blebbing into the canalicular lumen were seen. Coarsely granular "Byler bile", tight-junction abnormalities, and cholangiocellular primary cilia were not identified ( Figure 3A ).
Discussion
Neonatal sclerosing cholangitis is a rare and severe form of cholangiopathy. Among our 29 patients, 4 died in childhood (14%). More than half (18) developed end-stage liver disease as children, with LT performed in 16. Liver disease like that of NSC has not recurred after LT.
Utilising WES, we identified mutations in DCDC2 (OMIM #605755) in a subgroup of NSC patients. The encoded protein, DCDC2, is part of the microtubule structure involved in ciliary function. DCDC2 belongs to the doublecortin gene family, the first identified member of which is DCX (OMIM #300067). Mutations in DCX, located at Xq23, are associated with subcortical band heterotopia in females and lissencephaly in males [15] . In humans and mouse 11 paralogs in the DCX-repeat gene family have been described [16] . Dcdc2 knockout mice exhibit multiply disrupted development in memory capacity and phonological processing as well as bile duct proliferation and liver fibrosis [17, 18] .
Five different mutations in DCDC2 (3 frameshift, 2 introducing premature stop codons; all protein-truncating) were identified in 7 NSC patients, with variants found in exons 1, 4, 5, 6, and 7. The DCDC2 locus contains an antisense transcript, KAAG1 (or RU2AS), on the opposite DNA strand. Six of 7 mutations are predicted to have no effect on this transcript.
Only 1 of the 7 mutations was present in the antisense transcript. That our patients' phenotype is the consequence of mutational effects on this other transcript, rather than on that of DCDC2, thus seems highly unlikely. [19, 20] . These findings indicate that primary cilia fail to develop normally when biallelic protein-truncating mutation in DCDC2 is present. How loss of ciliary integrity predisposes to inflammation and cholestasis, with the phenotype of neonatalonset cholangiopathy, is at present unclear [21] . We suggest that the absence of DCDC2 may be implicated either in the formation of "cytotoxic" bile or in dysregulation of the cholangiocyte's homeostatic mechanisms, perhaps via Wnt signalling [17] .
Cilia are structures enclosed by the plasma membrane of eukaryotic cells. They are divided into motile cilia such as those of respiratory and genital-tract mucosa and primary cilia (also known as sensory cilia) such as those of cholangiocytes [22] . Specialised cilia also exist, such as the kinocilia of neuroepithelium (see below). Each primary cilium consists of a microtubule-based axoneme and a basal body -a centriole-based microtubule centre from which the axoneme is derived. Primary cilia, when compared to motile cilia, have the basic structure of the 9+0 microtubule arrangement. However, they lack the inner and outer dynein arms and radial spokes of motile cilia, and consequently are non-motile.
Cholangiocyte cilia were first identified in mice in 1963 [23] . this attachment affects the extracellular signal-regulated kinase signalling pathway and influences cell proliferation [24, 25] . Thirdly, cilia act as osmotic sensors. As bile traverses the biliary tract, its osmolality alters due to absorption of bile acids and glucose, or to secretion of bicarbonate ions and water. Transient receptor potential vallinoid type 4 channels regulate intracellular ionised-calcium concentrations in response to changes in osmolality and biliary secretion, with increased cholangiocyte proliferation [26] .
DCDC2 has been identified as a candidate gene for dyslexia [27] . DCDC2 is highly expressed in the central nervous system throughout foetal and adult life. It is also present in other organs, including the liver. DCDC2 contains two doublecortin domains, previously described in DCX. These domains are microtubule-binding modifiers. Microtubules are involved in cytoskeletal structure, cell movement and division, and intracellular transport.
They are a key component of the internal structure of cilia. Microtubule-associated proteins (MAPs) have a regulatory role mediated via binding to microtubules in a nucleotideindependent process [28] . DCDC2, a known MAP, has the potential to interfere with tubulin binding and microtubule polymerisation, and accordingly with development of normal ciliary structure [28] , as suggested by the lack of ACALT in our DCDC2-mutated patients. Ciliary proteins are synthesized in the cytoplasm and endoplasmic reticulum and transported within the cilium via the intraflagellary transport system, which is important in multiple ciliary functions. This system, composed of 20 proteins, relies on kinesin-2 or dyneine 2/1b. It operates along microtubules. MAPs such as DCDC2 affect its operation [29] . DCDC2, as a MAP, is localised at the ciliary axoneme, where it interacts with both the sonic hedgehog and the Wnt signalling pathways [17, [29] [30] [31] .
Disorders associated with variants in DCDC2 have been described. A homozygous point mutation in DCDC2 (c.1271A>C, p.Gln424Pro) was reported in a Tunisian family with nonsyndromic autosomal recessive hearing loss [10] . Immunofluorescence studies in rat inner ear neuroepithelial tissue found that Dcdc2 localized to the primary cilia of nonsensory supporting cells and the kinocilia of sensory hair cells (a type of cilium on the apex of hair cells located in the sensory epithelium of the vertebrate inner ear), with increased density toward the tip. They also demonstrated that DCDC2 mutation could deregulate kinociliary axoneme length and stability with consequent loss of cell function [10] .
Nephronophthisis-related ciliopathies (NPHP-RC) are associated with mutations in a variety of genes [32] [33] [34] [35] [36] [37] [38] [39] . A recent study of 100 consanguine patients with NPHP-RC identified a homozygous truncating mutation in DCDC2 (the same as that in our patient 1) in a single patient who also had liver disease. High-throughput exon sequencing of DNA from another 800 NPHP-RC families in the study found compound heterozygosity for two mutations in DCDC2, a frameshift mutation (the same as that in our patient 6) and a splice site mutation (c.349-2A>G), in a single patient with hepatic fibrosis but no renal disease up to age of 9 years. Whilst no specific liver phenotype-genotype correlations were found in the patients studied, hepatic portal fibrosis and bile duct proliferation were documented in Dcdc2 knockout mice; in addition, interaction between DCDC2 and Wnt signaling was confirmed in IMCD3 and NIH3T3 cell culture, as was localisation of DCDC2 in the ciliary axoneme and mitotic spindle fibres [17] .
Hepatorenal fibrocystic diseases, commonly known as ciliopathies, include autosomaldominant and -recessive polycystic kidney diseases [40, 41] and Joubert [42] , Jeune [43] , Bardet-Biedl [44] , Meckel-Gruber [45] , and oro-facial-digital syndromes [46] . Liver manifestations have been described in congenital hepatic fibrosis, Caroli disease, Jeune and Caroli syndromes [43, 47, 48] , and polycystic liver disease [49] , with gene mutations confirmed in a proportion of affected patients [50] . Based on our data, a subset of NSC should be included among the ciliopathies.
In our patients with DCDC2 mutations, only one manifested chronic renal disease, although another had a small renal cyst and another suffered transient renal impairment during an episode of liver failure. Other features of hepatorenal ciliopathies, such as osteochondrodysplasia or multiorgan cystic change, were not observed, and central nervous system dysfunction or hearing loss -potential concerns, given the pattern of DCDC2 expression in early life and observations noted above -were not recognised. Our identification of DCDC2 mutations in NSC patients, mostly without renal involvement, suggests a distinct type of ciliopathy.
Of particular interest in DCDC2 deficiency is that biliary-tract inflammation, with scarring and cholestasis, predominates clinically. This is not the case in other hepatorenal ciliopathies.
The predominance of liver disease over kidney disease in patients with mutations in DCDC2 highlights differences in the function of primary cilia between the two organs. The mechanisms underlying these differences remain to be determined. Stimuli generated by alterations of bile composition in the proximal biliary tract, and of urine composition in tubuloglomerular structures, could potentially direct different microtubular responses, with organ-specific, distinct phenotypes, such as that described in our probands. In the liver, we can only speculate on whether impairment of DCDC2-mediated function alters bile composition, making bile more damaging, or lowers cholangiocyte defences against normal bile. However, study of bile-mediated injury pathways could improve our understanding of NSC as well as of other early onset cholangiopathies, such as biliary atresia (in which indeed ciliary abnormalities are described) [19, 20] . We anticipate that study of DCDC2 function and dysfunction will provide insights into cholangiocyte biology and regulation of normal bile flow. 
